Elacestrant in metastatic breast cancer: Is the “standard of care” meeting standard requirements?

Volume: 15, Issue: 1, Pages: 101273 - 101273
Published: Jan 1, 2022
Abstract
The EMERALD trial was an open label phase 3 trial evaluating elacestrant, the first oral selective estrogen receptor degrader (SERD), as compared to "standard of care", in ER+/HER2- (hormone receptor positive, no HER2 overexpression) advanced or metastatic breast cancer. The EMERALD trial restricted the "standard of care" control arm to limited options that may have led to a substandard control arm. We describe how the EMERALD trial protocol...
Paper Details
Title
Elacestrant in metastatic breast cancer: Is the “standard of care” meeting standard requirements?
Published Date
Jan 1, 2022
Volume
15
Issue
1
Pages
101273 - 101273
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.